Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metast...

por Obermannová, R., Van Cutsem, E., Yoshino, T., Bodoky, G., Prausová, J., Garcia-Carbonero, R., Ciuleanu, T., Garcia Alfonso, P., Portnoy, D., Cohn, A., Yamazaki, K., Clingan, P., Lonardi, S., Kim, T. W., Yang, L., Nasroulah, F., Tabernero, J.
Publicado 2016

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

por Tabernero, J, Hozak, R R, Yoshino, T, Cohn, A L, Obermannova, R, Bodoky, G, Garcia-Carbonero, R, Ciuleanu, T -E, Portnoy, D C, Prausová, J, Muro, K, Siegel, R W, Konrad, R J, Ouyang, H, Melemed, S A, Ferry, D, Nasroulah, F, Van Cutsem, E
Publicado 2018

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—...

por Yoshino, T, Portnoy, D C, Obermannová, R, Bodoky, G, Prausová, J, Garcia-Carbonero, R, Ciuleanu, T, García-Alfonso, P, Cohn, A L, Van Cutsem, E, Yamazaki, K, Lonardi, S, Muro, K, Kim, T W, Yamaguchi, K, Grothey, A, O’Connor, J, Taieb, J, Wijayawardana, S R, Hozak, R R, Nasroulah, F, Tabernero, J
Publicado 2019